205 related articles for article (PubMed ID: 22916428)
1. [Chronic hepatitis C: improved cure rates with new approved medications].
Grammatikos G; Vermehren J; Zeuzem S
MMW Fortschr Med; 2012 Jun; O 154 Suppl 2():65-9; quiz 70. PubMed ID: 22916428
[No Abstract] [Full Text] [Related]
2. Maximizing opportunities and avoiding mistakes in triple therapy for hepatitis C virus.
Barritt AS; Fried MW
Gastroenterology; 2012 May; 142(6):1314-1323.e1. PubMed ID: 22537438
[TBL] [Abstract][Full Text] [Related]
3. [Therapy of chronic hepatitis C].
Schaffstein S; Rampini SK; Müllhaupt B
Praxis (Bern 1994); 2014 Apr; 103(8):423-36. PubMed ID: 24713377
[No Abstract] [Full Text] [Related]
4. [Telaprevir, PEG-IFNα-2b and ribavirin combination therapy for difficult to treat patients with genotype 2 chronic hepatitis C].
Nishimura T
Nihon Rinsho; 2015 Dec; 73 Suppl 9():193-8. PubMed ID: 26845929
[No Abstract] [Full Text] [Related]
5. [Use of boceprevir and telaprevir in patients with hepatitis C virus infection (practical considerations)].
Crespo G; Lens S
Gastroenterol Hepatol; 2012 May; 35(5):337-43. PubMed ID: 22349607
[TBL] [Abstract][Full Text] [Related]
6. Impact of HCV protease-inhibitor-based triple therapy for chronic HCV genotype 1 infection.
Ferenci P; Reddy KR
Antivir Ther; 2011; 16(8):1187-201. PubMed ID: 22155901
[TBL] [Abstract][Full Text] [Related]
7. UK consensus guidelines for the use of the protease inhibitors boceprevir and telaprevir in genotype 1 chronic hepatitis C infected patients.
Ramachandran P; Fraser A; Agarwal K; Austin A; Brown A; Foster GR; Fox R; Hayes PC; Leen C; Mills PR; Mutimer DJ; Ryder SD; Dillon JF
Aliment Pharmacol Ther; 2012 Mar; 35(6):647-62. PubMed ID: 22296568
[TBL] [Abstract][Full Text] [Related]
8. [Treatment of chronic hepatitis viral C: new associations].
Ouzan D
Presse Med; 2013 Jun; 42(6 Pt 1):977-82. PubMed ID: 23021659
[TBL] [Abstract][Full Text] [Related]
9. Effects of Smoking on Pegylated Interferon alpha 2a and First Generation Protease Inhibitor-based Antiviral Therapy in Naïve Patients Infected with Hepatitis C Virus Genotype 1.
Zimmermann T; Hueppe D; Mauss S; Buggisch P; Pfeiffer-Vornkahl H; Grimm D; Galle PR; Alshuth U
J Gastrointestin Liver Dis; 2016 Mar; 25(1):15-24. PubMed ID: 27014750
[TBL] [Abstract][Full Text] [Related]
10. [New agents for the treatment of hepatitis C].
Buti M; Homs M
Enferm Infecc Microbiol Clin; 2012 Mar; 30(3):147-50. PubMed ID: 22118805
[TBL] [Abstract][Full Text] [Related]
11. [Triple therapy in cirrhotic patients and those with advanced fibrosis: relevant aspects in clinical practice].
Albillos A; Luis Calleja J; Molina E; Planas R; Romero-Gómez M; Turnes J; Hernández-Guerra M
Gastroenterol Hepatol; 2014 Jul; 37 Suppl 1():13-22. PubMed ID: 25907434
[TBL] [Abstract][Full Text] [Related]
12. Triple therapy with boceprevir for HCV genotype 1 infection: phase III results in relapsers and nonresponders.
Bacon BR; Khalid O
Liver Int; 2012 Feb; 32 Suppl 1():51-3. PubMed ID: 22212572
[TBL] [Abstract][Full Text] [Related]
13. Summaries for patients. Re-treating patients with chronic hepatitis C who have not responded to peginterferon-alpha2b.
Ann Intern Med; 2009 Apr; 150(8):I-34. PubMed ID: 19380849
[No Abstract] [Full Text] [Related]
14. Chronic hepatitis C virus infection in 2013--quo vadis?
Prelipcean CC; Mihai C
Rev Med Chir Soc Med Nat Iasi; 2013; 117(1):7-10. PubMed ID: 24505885
[No Abstract] [Full Text] [Related]
15. Current and emerging antiviral treatments for hepatitis C infection.
Doyle JS; Aspinall E; Liew D; Thompson AJ; Hellard ME
Br J Clin Pharmacol; 2013 Apr; 75(4):931-43. PubMed ID: 22882367
[TBL] [Abstract][Full Text] [Related]
16. Boceprevir for chronic HCV genotype 1 infection.
Limaye AR; Draganov PV; Cabrera R
N Engl J Med; 2011 Jul; 365(2):176; author reply 177-8. PubMed ID: 21751914
[No Abstract] [Full Text] [Related]
17. [Effectiveness and safety of antiviral therapy of military personnel suffering from chronic hepatitis C].
Zhdanov KV; Gusev DA; Kozlov KV; Shishkin MK; Sukachev VS; Shakhmanov DM; Zhabrov SS
Voen Med Zh; 2015 Apr; 336(4):44-9. PubMed ID: 26454938
[TBL] [Abstract][Full Text] [Related]
18. The prospective randomized study on telaprevir at 1500 or 2250 mg with pegylated interferon plus ribavirin in Japanese patients with HCV genotype 1.
Oze T; Hiramatsu N; Yakushijin T; Yamada R; Harada N; Morishita N; Yamada A; Oshita M; Kaneko A; Suzuki K; Inui Y; Tamura S; Yoshihara H; Imai Y; Miyagi T; Yoshida Y; Tatsumi T; Kasahara A; Hayashi N; Takehara T
J Gastroenterol; 2015 Mar; 50(3):313-22. PubMed ID: 24806033
[TBL] [Abstract][Full Text] [Related]
19. Boceprevir: a protease inhibitor for the treatment of chronic hepatitis C.
Foote BS; Spooner LM; Belliveau PP
Ann Pharmacother; 2011 Sep; 45(9):1085-93. PubMed ID: 21828346
[TBL] [Abstract][Full Text] [Related]
20. Telaprevir twice daily is noninferior to telaprevir every 8 hours for patients with chronic hepatitis C.
Buti M; Agarwal K; Horsmans Y; Sievert W; Janczewska E; Zeuzem S; Nyberg L; Brown RS; Hézode C; Rizzetto M; Paraná R; De Meyer S; De Masi R; Luo D; Bertelsen K; Witek J
Gastroenterology; 2014 Mar; 146(3):744-753.e3. PubMed ID: 24316262
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
